A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 114
- Population
- ALL · 70 Years
- Duration
- 2007-02-01 to 2010-12-01
- Intervention
- erlotinib [Tarceva]; vinorelbine
- Comparator
- 2
- Outcomes measured
- Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR) — Scree…; Percentage of Participants Achieving Disease Control — Screening, Day 1 of Cycles 3 and 5 and at End of treatment up to…; Duration of Response Among Participants Who Achieved Either a CR or PR — Screening, Day 1 of Cycles 3 and 5, every 4th…; Percentage of Participants With Disease Progression — Day 1 of Cycles 1, 3, and 5 or first documentation of progressive…; Time to Disease Progression — Day 1 of Cycles 1, 3, and 5 or first documentation of progressive disease or death; Overall Survival: Percentage of Participants With an Progressive Disease or Death — Day 1 of Cycles 1 through 6 to date…; Overall Survival: Time to Event — Day 1 of Cycles 1 through 6 to date of death or date of last follow-up assessment; Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT) Questionnaire — Baseline and Day 1 of…; Changes in Quality of Life as Measured by the FACT Questionnaire — Baseline and Day 1 of Cycles 2, 3, 4, 5, 6 and End o…; Percentage of Participants With Changes in Quality of Life as Measured by FACT Questionnaire Scores by Category of Chan…; Changes in Quality of Life as Assessed by FACT-L (Lung Symptoms) Questionnaire — Baseline and Day 1 of Cycles 2, 3, 4,…; Percentage of Participants With Changes in FACT-L (Lung Symptoms) by Category of Change — Baseline and End of study
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.